Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity

References

• Rodriguez-AbreuDBordoniAZuccaEEpidemiology of hematological malignanciesAnn Oncol200718Suppl 1i3i817311819
   PubMed Web of Science ®Google Scholar
• VisserOTramaAMaynadiéMIncidence, survival and prevalence of myeloid malignancies in EuropeEur J Cancer201248173257326622770878
   PubMed Web of Science ®Google Scholar
• DöhnerHEsteyEHAmadoriSDiagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood2010115345347419880497
   PubMed Web of Science ®Google Scholar
• ShahAAnderssonTM-LRachetBBjörkholmMLambertPCSurvival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based studyBr J Haematol2013162450951623786647
   PubMed Web of Science ®Google Scholar
• LuLJRanderathKLong term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivoMol Pharmacol19842635946036208475
   PubMedGoogle Scholar
• StresemannCLykoFModes of action of the DNA Methyltransferase inhibitors azacytidine and decitabineInt J Cancer2008123181318425818
   PubMed Web of Science ®Google Scholar
• KarahocaMMomparlerRLPharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapyClin Epigenetics201351323369223
   PubMed Web of Science ®Google Scholar
• BlumWGarzonRKlisovicRBClinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProc Natl Acad Sci2010107167473747820368434
   PubMed Web of Science ®Google Scholar
• LancetJECortesJEHoggeDEPhase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AMLBlood2014123213239324624687088
   PubMed Web of Science ®Google Scholar
• LancetJEUyGLCortesJEFinal results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AMLJ Clin Oncol20163415_suppl70007000
   Web of Science ®Google Scholar
• GriffithsEAChoyGRedkarSTavernaPAzabMKarpfARSGI-110: DNA methyltransferase inhibitor oncolyticDrugs Future201338853554326190889
   PubMed Web of Science ®Google Scholar
• VijayaraghavaluSLabhasetwarVEfficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletionCancer Lett2013331112212923305699
   PubMed Web of Science ®Google Scholar
• HeurtaultBSaulnierPPechBProustJ-EBenoitJ-PA novel phase inversion-based process for the preparation of lipid nanocarriersPharm Res200219687588012134960
   PubMed Web of Science ®Google Scholar
• HuynhNTPassiraniCSaulnierPBenoitJPLipid nanocapsules: a new platform for nanomedicineInt J Pharm2009379220120919409468
   PubMed Web of Science ®Google Scholar
• LagarceFPassiraniCNucleic-acid delivery using lipid nanocapsulesCurr Pharm Biotechnol201617872372727033510
   PubMedGoogle Scholar
• HureauxJLagarceFGagnadouxFToxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in micePharm Res201027342143020054705
   PubMed Web of Science ®Google Scholar
• HureauxJLacoeuilleFLagarceFAbsence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in ratsInt J Nanomedicine2017128159817029184405
   PubMedGoogle Scholar
• ThomasOLagarceFLipid nanocapsules: a nanocarrier suitable for scale-up processJ Drug Delivery Sci Technol2013236555559
   Google Scholar
• BriotTRogerELautramNVergerAClavreulALagarceFDevelopment and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemiaInt J Nanomedicine2017128427844229200853
   PubMed Web of Science ®Google Scholar
• KantarjianHMThomasXGDmoszynskaAMulticenter, ran-domized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaJCO2012302126702677
   PubMed Web of Science ®Google Scholar
• LinKTMomparlerRLRivardGEHigh-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidineJ Pharm Sci19817011122812326170748
   PubMed Web of Science ®Google Scholar
• TománkováHZýkaJStudy of the time dependence of the stability of 5-aza-2′-deoxycytidine in acid mediumMicrochem J 1980/09/01/1980253281288
   Google Scholar
• Kim SunHHeeb RitaMKrämerIPhysicochemical stability of reconstituted decitabine (Dacogen®) solutions and ready-to-administer infusion bags when stored refrigerated or frozenPharmaceutical Technology in Hospital Pharmacy22017145
   Google Scholar
• HureauxJLagarceFGagnadouxFLipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxelEur J Pharm Biopharm200973223924619560538
   PubMed Web of Science ®Google Scholar
• MoysanEBastiatGBenoitJ-PGemcitabine versus modified gemcitabine: a review of several promising chemical modificationsMol Pharm201310243044422978251
   PubMed Web of Science ®Google Scholar
• BergmanAMKuiperCMVoornDAAntiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosyl-cytosine in leukemia and solid tumor cell linesBiochem Pharmacol200467350351115037202
   PubMed Web of Science ®Google Scholar
• BergmanAMAdemaADBalzariniJAntiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor modelsInvest New Drugs201129345646620066470
   PubMed Web of Science ®Google Scholar
• QinTJelinekJSiJShuJIssaJ-PJMechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell linesBlood2009113365966718931345
   PubMed Web of Science ®Google Scholar
• IssaJ-PJRobozGRizzieriDSafety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyLancet Oncol20151691099111026296954
   PubMed Web of Science ®Google Scholar
• SaliouBThomasOLautramNDevelopment and in vitro evaluation of a novel lipid nanocapsule formulation of etoposideEur J Pharm Sci201350217218023831519
   PubMed Web of Science ®Google Scholar
• RogerELagarceFBenoitJ-PDevelopment and characterization of a novel lipid nanocapsule formulation of SN38 for oral administrationEur J Pharm Biopharm201179118118821303693
   PubMed Web of Science ®Google Scholar
• NeupaneYRSrivastavaMAhmadNKumarNBhatnagarAKohliKLipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessmentInt J Pharm20144771–260161225445972
   PubMed Web of Science ®Google Scholar
• DulieuCBazileDInfluence of lipid nanocapsules composition on their aptness to freeze-dryingPharm Res200522228529215783077
   PubMed Web of Science ®Google Scholar
• TaoWZhaoDSunMIntestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymesInt J Pharm20185411–2647129471144
   PubMedGoogle Scholar
• ZhangYSunJGaoYA carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabineMol Pharm20131083195320223822717
   PubMedGoogle Scholar
• ClouserCLBonnacLManskyLMPattersonSECharacterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugsAntivir Chem Chemother201423622323023994876
   PubMedGoogle Scholar
• Garcia-ManeroGOdenikeOAmreinPCSuccessful emulation of IV decitabine pharmacokinetics with an oral Fixed-dose combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with oral decitabine, in subjects with myelodysplastic syndromes (MDS): final data of phase 1 studyAm Soc Hematology2016
   Google Scholar
• LavelleDVaitkusKLingYEffects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineBlood201211951240124722160381
   PubMed Web of Science ®Google Scholar
• SloatBRSandovalMALiDIn vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticlesInt J Pharm20114091–227828821371545
   PubMedGoogle Scholar
• LainéA-LClavreulaRousseauaInhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsulesNanomedicine20141081667167724842766
   PubMedGoogle Scholar
• PaillardAHindréFVignes-ColombeixCBenoitJ-PGarcionEThe importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailabilityBiomaterials201031297542755420630585
   PubMed Web of Science ®Google Scholar
• HollenbachPWNguyenANBradyHA comparison of azaciti-dine and decitabine activities in acute myeloid leukemia cell linesPLoS One201052e900120126405
   PubMed Web of Science ®Google Scholar
• VijayaraghavaluSDermawanJKCheriyathVLabhasetwarVHighly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrestMol Pharm201310133735223215027
   PubMed Web of Science ®Google Scholar
• ThépotSLaineyECluzeauTHypomethylating agents reactivate FOXO3a in acute myeloid leukemiaCell Cycle201110142323233021654193
   PubMed Web of Science ®Google Scholar
• LiuZMarcucciGByrdJCGreverMXiaoJChanKKCharac-terization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification methodRapid Commun Mass Spectrom20062071117112616523529
   PubMedGoogle Scholar
• XuHLvSQiaoMDevelopment and validation of a liquid chromatography–tandem mass spectrometry method for quantification of decitabine in rat plasmaJournal of Chromatography B20128998185
   PubMedGoogle Scholar
• SassoMSLolloGPitorreMLow dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapyBiomaterials201696476227135716
   PubMed Web of Science ®Google Scholar
• LainéA-LGravierJHenryMConventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoringJ Control Release20141881824878182
   PubMed Web of Science ®Google Scholar
• GrooACBossiereMTrichardLLegrasPBenoitJPLagarceFIn vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumorNanomedicine201510458960125723092
   PubMed Web of Science ®Google Scholar